This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Corvus Pharmaceuticals’s 8K filing here.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
Featured Articles
- Five stocks we like better than Corvus Pharmaceuticals
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- AppLovin’s AI Potential: Can the Momentum Continue?
- How to Calculate Return on Investment (ROI)
- Global Macro Hedge Funds Dominated 2024: Strategies You Can Copy
- What is a Special Dividend?
- These 3 Space Stocks Soared in 2024: Can the Momentum Last?
